TIRAT CARMEL, Israel, April 22, 2010 /PRNewswire/ -- The ExAblate(R) 2000, a magnetic resonance guided focus ultrasound system, received special recognition by being included in the 10th nationwide Girls' Day in Germany. This event held on April 21st, 2010 at the German Federal Chancellery, celebrates innovation, science and technology and encourages school girls to consider science as a career. Chancellor Merkel, accompanied by a group of 24 schoolgirls, visited the booth of Techniker Krankenkasse (TK), a prominent German health insurance company, observed a demonstration of the ExAblate system at work and heard an explanation by Dr. Matthias Matzko of the Amper Kliniken AG in Dachau.

(Photo: http://www.newscom.com/cgi-bin/prnh/20100422/387687 )

Each year hundreds of thousands of women across Europe are diagnosed with uterine fibroids and until now, many have had to resort to hysterectomies to alleviate the symptoms of this often devastating condition.

This technology has the potential to improve the health care of thousands of women across Europe. It is important that women with uterine fibroids now have a choice of a non-invasive treatment and furthermore may be able to protect their future fertility, said Dr. Matthias Matzko of the Amper Kliniken AG in Dachau. The Amper Kliniken is one of four treatment centers in Germany that offer this innovative technology to women. The clinic worked with Techniker Krankenkasse (TK) to become the first German health insurance offering reimbursement for this new technique for the treatment of uterine fibroids. The ExAblate treatment is administered at more than 30 leading hospitals across Europe.

TK wants to advance reasonable and promising medical innovations, so that our contract patients with uterine fibroids may already benefit from this gentle treatment. Patients do not need to wait for years until this procedure will be integrated in the basic coverage. explained Mr. Lütjohann, the head of the myoma project treatment at TK.

Amper Kliniken provides a great example of what can be achieved when a treatment center works with the healthcare provider looking for ways to improve patient care said Dr. Kobi Vortman, President and Chief Executive Officer of InSightec.

The ExAblate 2000 system destroys non-invasively the fibroids using high intensity focused ultrasound waves to ablate the fibroids. The surrounding tissue is spared, and the level of adverse events is very low compared to other treatment alternatives.

ExAblate has CE and FDA approval for the treatment of Uterine Fibroids and a CE approval for the treatment of bone metastases. MRgFUS technology is being investigated in such areas as bone metastases, breast, liver, brain and prostate cancer in clinical trials sponsored by InSightec around the world.

About Uterine Fibroids Uterine fibroids are benign growths in the uterus that affect more than 30% of women of childbearing age. Symptomatic women suffer from extensive and prolonged menstrual bleeding, anaemia, pain, pressure and often infertility. Existing treatment options include hysterectomy, myomectomy and uterine artery embolization that are invasive and minimally invasive, involving hospitalization and several weeks of recovery time. ExAblate is an outpatient procedure and patients return home the same day and to work within one to two days.

About ExAblate(R)

ExAblate is the first system to use the breakthrough MRgFUS technology that combines MRI - to visualize the body anatomy, plan the treatment and monitor treatment outcome in real time - and high intensity focused ultrasound to thermally ablate tumors inside the body non-invasively. MR thermometry, provided uniquely by the system, allows the physician to control and adjust the treatment in real time to ensure that the targeted tumor is fully treated and surrounding tissue is spared. Approved by the U.S. Food and Drug Administration in 2004 as a treatment for symptomatic uterine fibroids, ExAblate has been recognized for its innovation and potential to serve mankind and has been awarded the 2004 European Union's Information Society Technologies grand prize, The Wall Street Journal's 2004 Technology Innovation Awards, Advanced Imaging's 2005 Solutions of the Year, the Red Herring 100 Europe 2007 Award and currently one of the World Economic Forum Technology Pioneer 2008.

About InSightec

InSightec Ltd. is a privately held company owned by Elbit Imaging (EI), General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 160 employees and has invested in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/

For further information please contact: InSightec Ltd. P.O. Box 2059 Tirat Carmel 39120, Israel Tel: +972-4-813-1313 Fax: +972-4-813-1322 Email: info@insightec.com Media contact Waggener Edstrom Worldwide-London Waggener Edstrom Worldwide - London Dr Jane Brearley Healthcare Practice EMEA T +44(0)20-7632-3897 jbrearley@waggeneredstrom.com

SOURCE: InSightec Ltd

CONTACT: InSightec Ltd., P.O. Box 2059, Tirat Carmel 39120, Israel, Tel:+972-4-813-1313, Fax: +972-4-813-1322, Email: info@insightec.com; Mediacontact Waggener, Edstrom Worldwide-London, Waggener Edstrom Worldwide -London, Dr Jane Brearley, Healthcare Practice EMEA, T +44(0)20-7632-3897,jbrearley@waggeneredstrom.com